Citations

Clear

16280 citation(s) found for "Yu, David".

Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis
Rangarajan, Hemalatha G. , Satwani, Prakash , Chen, Min , Wudhikarn, Kitsada , Marks, David I. , Kelly, Matthew S. , Farhadfar, Nosha , Prestidge, Tim , Hossain, Nasheed , Liu, Hongtao , Hashmi, Shahrukh K. , Modi, Dipenkumar , Winestone, Lena E. , Boghdadly, Zeinab El , Chemaly, Roy F. , Dandoy, Christopher E. , Hill, Joshua A. , Huppler, Anna R. , Riches, Marcie , Herr, Megan M. , Martens, Michael J , Kelkar, Amar H , Ringden, Olov , Friend, Brian D , Kelly, Matthew S , Prestidge, Tim , Hossain, Nasheed M , Liu, Hongtao , Hashmi, Shahrukh K , Modi, Dipenkumar , Winestone, Lena E , Murthy, Hemant S , Perales, Miguel-Angel , Chemaly, Roy F , Dandoy, Christopher E , Hill, Joshua A , Huppler, Anna R , Auletta, Jeffery J , Martens, Michael J. , John, Samuel, Fabrizio, Vanessa A , Hsieh, Emily M. , Doherty, Erin , Ringdén, Olle , Murthy, Hemant S. , Perales, Miguel‐Angel , Auletta, Jeffery J.

Mayo Clinic

Blood Advances | July 30, 2025 | Volume: 9 | Issue: 21 | Pages: 5489-5500

10.1182/bloodadvances.2025016149 | PMID 40737539 Get It

Abstract Tisagenlecleucel (tisa-cel) is a CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory precursor B-cell acute lymphoblastic leukemia (R/R B-ALL). We report infectious complications for 100 days (D100) following tisa-cel therapy in 471 pediatric and young adults (median age 13.8 years) with R/R B-ALL reported from September 2017 to June 2022. By D100, 137 (29%) patients had an infectious event, with an infection density of 0.542 per 100 person-days at risk. D100 cumulative incidences of bacterial, viral, and fungal infections were 14.1%, 11.6%, and 1.3%, corresponding to infection density scores of 0.296, 0.213, and 0.033 per 100 person-days at risk, respectively. In a multivariable analysis, receipt of ≥3 lines of therapy before tisa-cel (hazard ratio [HR], 1.86; 95% confidence interval [CI], 1.13-3.08; P = .015), any-grade cytokine release syndrome (HR, 1.78; 95% CI, 1.17-2.71; P = .007), and lack of neutrophil recovery (HR, 2.63; 95% CI, 1.47-4.69; P = .001) were associated with an increased risk for any infection. Similar associations were observed for bacterial infections, with the addition of younger age as an adverse risk (<6 vs 6-15 years; HR, 2.38; 95% CI, 1.23-4.61; P = .01). Risk factors for viral infections included increasing age (1-year increase; HR, 1.05; 95% CI, 1.01-1.09; P = .016), prior history of any infection (HR, 2.76, 95% CI, 1.40-5.46; P = .004), and prior hematopoietic cell transplant (HR, 2.10; 95% CI, 1.18-3.71; P = .011). D100 infection-related mortality (IRM) rate was low at 0.2% (95% CI, 0.0-0.8). In this multicenter real-world study, we observed a high incidence of infectious complications but a low IRM following tisa-cel for R/R B-ALL.
Efficacy of Portable Fugitive Aerosol Mitigation Systems for Nebulizer Therapy During High-Flow Nasal Cannula and Non-Invasive Ventilation
Pandian, Adithya Shyamala , Patel, B. M. , Karam, Karam Abi , Lowell, Amelia , McKay, Kelly, Hota, Piyush , Pyznar, Gabriel , Batchelor, Sandra, Peworski, Charles, Rivas, David A., Sanghavi, Devang , Nguyen, Ngan Anh, Eltantawy, Aliaa, Li, Xueqi , Serhan, Michael , Forzani, Erica , Patel, Bhavesh M , Mora, Sabrina , Batchelor, Sandra, Peworski, Charles, Rivas, David, Xian, Xiaojun

Mayo Clinic

Emergency Care and Medicine | July 29, 2025 | Volume: 2 | Issue: 3 | Pages: 36

10.3390/ecm2030036 Get It

Objectives: This study evaluates the efficacy of existing and new aerosol mitigation methods during nebulization (Neb) in combination with high-flow nasal cannula (HFNC) oxygen supplementation and non-invasive ventilation (NIV). Methods: We recorded fugitive aerosol particle concentrations over time and assessed the peak (P) and area (A) efficacy of active and passive mitigation methods, comparing them to a no-mitigation condition. Peak efficacy was measured by the reduction in maximum aerosol concentration, while area efficacy was quantified by the reduction of the area under the aerosol concentration–time curve. Results: For HFNC with Neb, we found that active mitigation using a mask with a biofilter and a fan (referred to as the aerosol barrier mask) significantly outperformed passive mitigation with a face mask. The peak and area efficacy for aerosol reduction were 99.0% and 96.4% for active mitigation and 35.9% and 7.6% for passive mitigation, respectively. For NIV with Neb, the active mitigation method, using a box with a biofilter and fan, also outperformed passive mitigation using only the box. The peak and area efficacy for aerosol reduction were 92.1% and 85.5% for active mitigation and 53.7.0% and 25.4% for passive mitigation, respectively. Conclusion: We concluded that active mitigation set up systems advantageous for effective reduction of airborne aerosols during aerosol generated procedures.
The Impact of Frailty on Short‐Term Outcomes After Surgery for Zenker Diverticulum
Bass, Elisa , Lott, David G. , Zheng, Melissa , Lott, David G

Mayo Clinic

Otolaryngology–Head and Neck Surgery | July 29, 2025 | Volume: 173 | Issue: 4 | Pages: 947-953

10.1002/ohn.1367 | PMID 40728072 Get It

Abstract Objective Determine relationship between frailty and hospital mortality, length of stay, cost, and medical and surgical complications in Zenker diverticulum surgery. Study Design Retrospective cross‐sectional. Setting National database. Methods Data from the National Inpatient Sample for 712 patients who underwent surgery for Zenker diverticulum 2016 to 2021 were analyzed using multivariate regressions. Frailty was defined as at least 1 frailty‐defining diagnosis from the Johns Hopkins ACG® Frailty Indicator. Elixhauser Comorbidity Index was calculated to quantify comorbidity burden. Results 12.2% of patients were identified as frail, 77.0% of whom had a weight loss or malnutrition diagnosis. Frailty predicted increased length of stay (mean, 4.09 days [95% CI: 2.98‐5.20]) and increased costs (mean, $10,500.36 [95% CI: $6885.76‐$14,114.95]). Frail patients were more likely to have medical complications compared to non‐frail patients (OR = 2.84 [95% CI: 1.66‐4.84]). Elixhauser Comorbidity Index was predictive of hospital mortality (OR = 1.78 [95% CI: 1.27‐2.51]) and likelihood of endoscopic surgical complications (OR = 1.25 [95% CI: 1.05‐1.47]), but frailty was not predictive of either. Conclusion Frailty is not associated with increased risk of surgical complications or mortality and is not an absolute contraindication to Zenker diverticulum surgery. Frailty predicts length of stay, costs, and medical complications in Zenker diverticulum surgery and should be used with comorbidity to stratify patient risk for surgery. Prospective studies involving frail patients could help develop a standardized method for assessing surgical fitness, potentially expanding treatment options and improving outcomes for this population. Level of Evidence 2.
Surgical Management of Idiopathic Subglottic Stenosis During Pregnancy: A Multi‐Institutional Study
Awadallah, Andrew S. , Khalil, Yousuf H. , Bowen, Andrew J. , Ali, Hawa M. , Ring, Sydney , McCalla, Monet, Francis, David O. , Dailey, Seth H. , Edell, Eric S. , Ekbom, Dale C. , Bayan, Semirra L. , Ekbom, Dale , Bowen, Andrew Jay , Awadallah, Andrew , Francis, David O , Koster, Matthew J.

Mayo Clinic

The Laryngoscope | July 29, 2025 | Volume: 135 | Issue: 12 | Pages: 4767-4773

10.1002/lary.32464 | PMID 40726462 Get It

ABSTRACT Background Managing idiopathic subglottic stenosis (iSGS) during pregnancy presents distinct clinical challenges. As pregnancy is a naturally dyspneic state, the development of iSGS may exacerbate respiratory symptoms and compromise the airway—potentially impacting pregnancy and delivery decisions. This study characterizes surgical management strategies and outcomes in pregnant patients with symptomatic iSGS. Methods We conducted the largest known multi‐institutional retrospective review of pregnant patients who underwent endoscopic intervention for iSGS. Demographics, procedural details, anesthesia and medication use, and maternal and neonatal outcomes were analyzed. Results Twelve patients underwent 15 endoscopic procedures during pregnancy: 9 laser wedge excisions (8 CO 2 laser and 1 coblator) and 6 balloon dilations. Three additional procedures in different patients occurred postpartum (2–11 months after delivery). Higher‐risk pregnancies included two twin gestations, one patient with multiple surgeries during two different pregnancies, and two patients over age 35. Most interventions (87%) occurred in the second trimester. Fetal monitoring was performed preoperatively and postoperatively. Fentanyl and propofol were used in 88% and 94% of cases, respectively; rocuronium was the most common neuromuscular blocker (70%). One patient underwent balloon dilation via flexible bronchoscopy without anesthesia. Jet ventilation was used in 53% of cases, and Size C Kleinsasser laryngoscopes in 47%. Median procedure times were 75, 19, and 18 min for laser wedge excision, balloon dilation, and coblation, respectively. Most patients delivered full‐term with no surgical or postpartum complications. Conclusions Endoscopic intervention for iSGS during pregnancy appears safe and effective, even in high‐risk cases. These findings support individualized airway management and inform future practice. Level of Evidence 4.
Intercostal Nerve Cryoablation During Pectus Excavatum Surgery for Postoperative Pain Management
Notrica, David M. , McMahon, Lisa , Hahn, A. , Ndikintum, Nfii, Dua, Madelyn, Jaroszewski, Dawn E. , McMahon, Lisa E , Hahn, Alyssa , Dua, Madelyn

Mayo Clinic

Annals of Surgery | July 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000006855 | PMID 40720602 Get It

Objective: The objective of this study was to systematically review the literature-reported outcomes of CRYO compared to standard of care without CRYO (non-CRYO) after PEx repair. Summary Background Data: Surgical repair of pectus excavatum (PEx) via the Nuss or Ravitch procedures is associated with substantial postoperative pain. Intercostal nerve cryoablation (CRYO) performed during the primary surgical repair has been adopted as a non-opioid modality for pain management. Methods: A literature search was conducted in PubMed, Embase, and using additional online approaches to identify comparative studies of patients undergoing the Nuss or Ravitch procedure for PEx repair with CRYO versus non-CRYO between years 2014-24. Meta-analysis was performed to quantitatively evaluate primary outcomes of hospital length of stay (LOS) and opioid consumption. Secondary outcomes were hospital costs and complications, summarized qualitatively. Results: Of 178 studies, 32 comparative studies encompassing 13,103 patients were included; 28% (n=3,620) received CRYO. Random effects meta-analyses demonstrated a significantly shortened LOS by 1.8 days (95% confidence interval [CI]: -2.12, -1.42) and a significant reduction in inpatient and outpatient opioid consumption with CRYO by 186 morphine mg equivalents (MME) (95% CI: -262.26, -109.08) and 147 MME (95% CI: -255.72, -38.26), respectively. Complications with CRYO were either decreased or similar between groups and resolved over time. Hospital costs were similar. Conclusions: This systematic review suggests CRYO during PEx repair is associated with a significantly shorter hospital LOS, as well as decreased opioid consumption both in the hospital and after discharge. Complications were infrequent and time-limited.
Comparative evaluation of recombinant thrombin and fibrin hydrogel systems for extracellular vesicle delivery
Yeleswarapu, Sriya , Tchoukalova, Yourka D. , Dicker, Kevin T., Celaya, Ava Koehler De, Gadalla, Dina , Hoelzinger, Dominique B. , Richards, Amanda, Zhang, Nan , Myers, Cheryl , Lott, David G. , Tchoukalova, Yourka , Koehler De Celaya, Ava, Richards, Amanda M, Myers, Cheryl E , Lott, David G , Richards, Amanda M.

Mayo Clinic

Biomaterials Science | July 28, 2025 | Volume: 13 | Issue: 18 | Pages: 5040-5051

10.1039/d5bm00705d | PMID 40719199 Get It

Comparative analysis of fibrin sealant and recombinant thrombin hydrogels reveals distinct microarchitectures and cellular responses, emphasizing recombinant thrombin’s potential to enhance cellular activity and enable vesicle delivery.
Anti‐Tumor Activity of Paclitaxel‐Containing Regimens in Recurrent/Refractory Wilms Tumor
Groisser, Alissa , Frantz, Amy, Geller, James I. , Ortiz, Michael V. , Walterhouse, David , Ranalli, Mark , Woods‐Swafford, Wendy, Schoettler, Peter , Garrington, Timothy , Mullen, Elizabeth A. , Ash, Shifra , Bardhan, Pooja, Dome, Jeffrey S. , Dome, Jeffrey S , Groisser, Alissa R. , Balis, Frank M.

Mayo Clinic

Pediatric Blood & Cancer | July 26, 2025 | Volume: 72 | Issue: 10 | Pages: No page available

10.1002/pbc.31915 | PMID 40714994 Get It

ABSTRACTBackgroundThe Pediatric Oncology Group P9262 Phase 2 study of single‐agent paclitaxel demonstrated one complete response (CR), one partial response (PR), and four with stable disease (SD) among 15 patients with recurrent Wilms tumor (WT). Based on this activity, paclitaxel‐containing regimens have been used as salvage therapy for treatment‐refractory WT. We conducted a multi‐institutional retrospective study to further characterize the clinical activity of paclitaxel‐containing regimens in recurrent WT.MethodsTwelve institutions submitted anonymized data from patients with relapsed WT treated with paclitaxel. Response after one or two cycles of a paclitaxel‐containing regimen was reported according to Response Evaluation Criteria in Solid Tumors.ResultsTwenty‐eight patients with a median age at diagnosis of 5.5 years (range: 3 months to 31.9 years) were reported. Twenty had non‐anaplastic WT; eight had diffuse anaplasia (DA). Stage at diagnosis was I (n = 1), II (n = 1), III (n = 11), IV (n = 14), and V (n = 1). Patients received a mean of 8.5 anticancer drugs (range: 6–12) before paclitaxel, including eight who received high‐dose therapy/stem cell transplant. Paclitaxel (n = 13) or nab‐paclitaxel (n = 15) were predominantly administered in combination with other agents, most commonly doxorubicin and/or gemcitabine. Eleven of 26 patients with measurable disease had a partial response (7 = non‐anaplastic; 4 = DA), four had stable disease, and 11 had progressive disease. Two patients without measurable disease maintained a complete response for 12 and 16 months. The mean duration without progression was 7.6 months (range: 1–35 months).ConclusionsPaclitaxel‐containing regimens appear to be active against heavily pretreated WT with either non‐anaplastic or DA histology. Prospective studies are warranted to formally evaluate the efficacy of paclitaxel‐based therapies.
Venous Thromboembolism Outcomes Among Cancer and Non-cancer Patients Managed with Patient-centric Guideline-driven Protocol
Cassianni, Claire , Vlazny, Danielle T. , Hodge, David O. , Cassianni, Claire E , McBane, Robert D. , Casanegra, Ana I. , Houghton, Damon E. , Wysokiński, Waldemar E.

Mayo Clinic

Thrombosis and Haemostasis | July 25, 2025 | Volume: 126 | Issue: 05 | Pages: 518-525

10.1055/a-2653-6161 | PMID 40719144 Get It

Abstract Patients with cancer and venous thromboembolism (VTE) have higher complication rates of anticoagulation. However, studies supporting this data are relatively old reflecting the era of vitamin K inhibitors. To assess VTE recurrence, major bleeding, and clinically relevant non-major bleeding (CRNMB) in patients (March 1, 2013 to April 30, 2023) with cancer-associated VTE and patients without cancer, the prospective Mayo Clinic Thrombophilia Clinic Registry was analyzed. Over the study period, 4,711 patients with acute VTE were enrolled including 2,064 patients with cancer (mean age 62.5 ± 12.4, 46% female) and 2,647 patients without cancer (mean age 59.4 ± 16.0, 45% female). The most common cancers were gastrointestinal (n = 423, 21%), pancreatic (n = 287, 14%), and genitourinary (n = 198, 10%). Direct oral anticoagulants were used in 1,339 (65%) cancer and in 1,952 (74%) non-cancer patients. Among cancer patients, 12-month Kaplan–Meier probability of VTE recurrence was 2.4-fold greater (7.1% vs. 2.9%, p < 0.001) compared with the non-cancer group, including higher recurrent leg deep vein thrombosis (3.0% vs. 1.4%; p = 0.002) and pulmonary embolism (3.5% vs. 1.0%, p < 0.001). Patients with cancer also had 2.1-fold greater risk of major bleeding (6.3% vs. 3.0%; p < 0.001) including bleeding from the gastrointestinal tract (3.0 vs. 1.4, p = 0.01) compared with patients without cancer. Clinically relevant non-major bleeding events were similar between the groups. In this large prospective registry of VTE management, patients with cancer had significantly higher rates of VTE recurrence and major bleeding compared with patients without cancer, yet the rate of complications are substantially smaller relative to historic values of a prior vitamin K antagonist era.
Midlife Retinal Microvascular Signs and Late-Life Neuroimaging Features of Cerebral Small Vessel Disease in the ARIC Study
Jiang, Kening , Power, Melinda C. , Bandeen‐Roche, Karen , Griswold, Michael , Albert, Marilyn , Knopman, David S. , Mosley, Thomas H. , Walker, Keenan A. , Sharrett, A. Richey, Egle, Marco , Mosley, Thomas H. , Knopman, David S. , Griswold, Michael , Albert, Marilyn S. , Gottesman, Rebecca F , Egle, Marco , Deal, Jennifer A , Walker, Keenan A , Gottesman, Rebecca F. , Deal, Jennifer A.

Mayo Clinic

Neurology | July 25, 2025 | Volume: 105 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000213919 | PMID 40712116 Get It

Same-Day Hospital Discharge Is Feasible for a Variety of Urologic Surgeries When Using a Virtual Hybrid Care Hotel
Hampton, Sarah, Perry, Alan G., Kumar, Neal, Hochwald, Alex, Ma, R. , Pak, Raymond W., Petrou, Steven P. , Thiel, David D. , Nazario, Maura, Pathak, Ram A. , Hochwald, Alex P, Ma, Renny, Dora, Chandler , Ma, Renny, Broderick, Gregory A. , Lyon, Timothy D. , Chadha, Ryan

Mayo Clinic

Urology Practice | July 25, 2025 | Volume: 12 | Issue: 6 | Pages: 683-690

10.1097/upj.0000000000000879 | PMID 40709932 Get It